PISCATAWAY, N.J. – Camber Pharmaceuticals announced the addition of valganciclovir for oral solution to its current portfolio.
Valganciclovir for oral solution is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for:
Adult Patients:
• Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
• Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.
Pediatric Patients:
• Prevention of CMV disease in kidney and heart transplant patients at high risk.
Valganciclovir for oral solution 50 mg/mL is available in 100mL bottles.
To find out more about valganciclovir for oral solution please visitwww.camberpharma.com
